Abstract
In Chinese medicine, Zheng-hou, instead of disease, is used to define complex medical problems in clinical practice. In the postgenomics era, it becomes particularly compelling to review the application of Zheng-hou in characterizing complex clinical problems independent of disease or syndrome. While disease or syndrome describes a pathological phenotype or phenotypes, Zheng-hou spells the pathological phenome. Clinical Zheng-hou pharmacology (CZP) is an emerging clinical discipline that aims to leverage breakthroughs in the genome-wide solutions for complex medical problems through a combination of the current “omics” technology and the knowledge of Chinese medicine. The concept of CZP suggests that systematic and standard studies of multiple phenotypes will be important because of the collaborative cross between diversified external and internal factors at different levels both in vitro and in vivo. In this paper, we discuss the novel phenomic approaches to the understanding of Zheng-hou and the link of pharmacogenomics to personalized medicine through CZP, or pharmacophenomics. CZP enables ever-finer mapping of Zheng-hou and detection of dynamic variations in most current omics platforms. Although major challenges still remain in identifying and effectively investigating the diversity of Zheng-hou, CZP is expected to pave new paths to the systemic understanding of medical problems. While still at early stages in the clinical phenome domain, there remains great promise that CZP can help us realize the application of personalized medicine and contribute to rational holistic diagnosis and treatment.
Keywords: Chinese medicine, Zheng-hou, Clinical Zheng-hou pharmacology, pharmacogenomics, personalized medicine, phenomic.
Current Vascular Pharmacology
Title:Clinical Zheng-hou Pharmacology: the Missing Link between Pharmacogenomics and Personalized Medicine?
Volume: 13 Issue: 4
Author(s): Ya-Nan Yu, Jun Liu, Lei Zhang, Zhong Wang, Dayue Darrel Duan and Yong-Yan Wang
Affiliation:
Keywords: Chinese medicine, Zheng-hou, Clinical Zheng-hou pharmacology, pharmacogenomics, personalized medicine, phenomic.
Abstract: In Chinese medicine, Zheng-hou, instead of disease, is used to define complex medical problems in clinical practice. In the postgenomics era, it becomes particularly compelling to review the application of Zheng-hou in characterizing complex clinical problems independent of disease or syndrome. While disease or syndrome describes a pathological phenotype or phenotypes, Zheng-hou spells the pathological phenome. Clinical Zheng-hou pharmacology (CZP) is an emerging clinical discipline that aims to leverage breakthroughs in the genome-wide solutions for complex medical problems through a combination of the current “omics” technology and the knowledge of Chinese medicine. The concept of CZP suggests that systematic and standard studies of multiple phenotypes will be important because of the collaborative cross between diversified external and internal factors at different levels both in vitro and in vivo. In this paper, we discuss the novel phenomic approaches to the understanding of Zheng-hou and the link of pharmacogenomics to personalized medicine through CZP, or pharmacophenomics. CZP enables ever-finer mapping of Zheng-hou and detection of dynamic variations in most current omics platforms. Although major challenges still remain in identifying and effectively investigating the diversity of Zheng-hou, CZP is expected to pave new paths to the systemic understanding of medical problems. While still at early stages in the clinical phenome domain, there remains great promise that CZP can help us realize the application of personalized medicine and contribute to rational holistic diagnosis and treatment.
Export Options
About this article
Cite this article as:
Yu Ya-Nan, Liu Jun, Zhang Lei, Wang Zhong, Duan Darrel Dayue and Wang Yong-Yan, Clinical Zheng-hou Pharmacology: the Missing Link between Pharmacogenomics and Personalized Medicine? , Current Vascular Pharmacology 2015; 13 (4) . https://dx.doi.org/10.2174/1570161112666141014144431
DOI https://dx.doi.org/10.2174/1570161112666141014144431 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Pharmacological Approaches in Infants with Hypoxic-Ischemic Encephalopathy
Current Pharmaceutical Design Involvement of Intracellular pH in Vascular Insulin Resistance
Current Vascular Pharmacology Protein Degradation Pathways after Brain Ischemia
Current Drug Targets Adalimumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Antibodies As Promising Novel Neuroprotective Agents in the Central Nervous System Injuries
Central Nervous System Agents in Medicinal Chemistry Classical and New Renin-Angiotensin Signalling in Atherosclerosis
Current Signal Transduction Therapy A Review of Systemic Vasodilators in Low Cardiac Output Syndrome Following Pediatric Cardiac Surgery
Current Vascular Pharmacology Translocator Protein (TSPO) and Neurosteroids: Implications in Psychiatric Disorders
Current Molecular Medicine Antiproliferative and Proapoptotic Effects of Proteasome Inhibitors and their Combination with Histone Deacetylase Inhibitors on Leukemia Cells
Cardiovascular & Hematological Disorders-Drug Targets Proteomics of the Dystrophin-glycoprotein Complex and Dystrophinopathy
Current Protein & Peptide Science Clopidogrel Desensitization: Background and Recommendations for Use of a Rapid (4 Hour) Protocol
Current Vascular Pharmacology Which way in? The Necessity of Multiple Approaches to Transcatheter Valve Therapy
Current Cardiology Reviews Anti-Diabetic Compounds and their Patent Information: An Update
Recent Patents on Inflammation & Allergy Drug Discovery Neuroprotective and Neurorestorative Effects of Epo and VEGF: Perspectives for New Therapeutic Approaches to Neurological Diseases
Current Pharmaceutical Design The Shift in the “Paradigm” of the Pharmacology of Hypertension
Current Topics in Medicinal Chemistry Gene Profiles within the Adult Subventricular Zone Niche:Proliferation, Differentiation and Migration of Neural Progenitor Cells in the Ischemic Brain
Current Molecular Medicine Pathophysiology and Treatment of Obesity Hypertension
Current Pharmaceutical Design Cardioprotection by Targeting the Pool of Resident and Extracardiac Progenitors
Current Drug Targets Cellular Redox Modulator, ortho Mn(III) meso-tetrakis(N-n-Hexylpyridinium-2-yl)porphyrin, MnTnHex-2-PyP5+ in the Treatment of Brain Tumors
Anti-Cancer Agents in Medicinal Chemistry Controversies in the Cath Lab: Navigating Contemporary Conundrums Before, During and After Intervention
Current Vascular Pharmacology